Platform Technology Webinar - February 18, 2021
Platform Technology: Is it possible to reduce vaccine development time?
An IABS webinar: Thursday, February 18, 2021 from 14 :00 – 16 :30 CET
Testimonials from J&J, Curevac and BioNtech
Round table discussion with Industry, EMA, FDA, Health Canada, PEI, WHO…
Platform Technology: what are the first experiences from different players who were allowed by the authorities to use data from other programs in a platform technology approach in order to shorten the development time.
Webinar Registration link : https://www.iabs.org/platform-technology-webinar.
IABS-EU_ZAPI Stakeholders Final Conference - February 4-5, 2021
ZAPI Stakeholders Final Conference
February 4-5, 2021
A Virtual Meeting
INFORMATION ABOUT THE MEETING HERE
In March 2015, IMI (Innovative Medicine Initiative - https://www.imi.europa.eu) launched ZAPI (Zoonotic Anticipation and Preparedness Initiative) to set up methodologies and platform technologies that would be ready to put into production for vaccines and neutralizing monoclonal antibodies to efficiently counter emerging or remerging zoonotic viruses.
“The objective is to demonstrate that we can deliver on these platforms, using three different prototype models of diseases that occurred in the recent past and which are zoonotic in nature.” The viruses that [have been] used as models are Middle East respiratory syndrome coronavirus (MERS-CoV); Schmallenberg virus; and Rift Valley Fever virus’. IMI ZAPI Interview
Six years later, the ZAPI project has made great strides in vaccine and antibody design, and new approaches for achieving the “surge manufacturing capacity” objective.
The Final Stakeholders Global Meeting will present an overview of the main findings and key learnings from the ZAPI project partnership’s experience for improving our One Health preparedness status for facing effectively future pandemics.
The ZAPI project benefits from the assistance and financial support of
IMI and the European Commission, and in-kind contributions from EFPIA partners.
6th Statistics Workshop - November 2-5, 2020, A Virtual Meeting
6th IABS Statistics Workshop:
Approaches for Improving Statistical Partnership in CMC Development,
Manufacturing, and Regulation of Biologicals
Due to restrictions associated with the SARS-COVID-2 pandemic,
the 6th IABS Statistics Workshop was held virtually.
6th STATISTICS WORKSHOP - SUMMARY
Approaches for Improving Statistical Partnership in CMC Development, Manufacturing, and Regulation of Biologicals was the 6th meeting in the series of IABS workshops focusing on Statistics and the role they play in the development of biotherapeutics and vaccines.
SARS-CoV-2 Webinar-An Update - October 16, 2020
An Update on SARS-CoV-2
Friday, October 16, 2020
The first IABS webinar (May 27th) provided insight into what was known at that point in time about SARS-CoV-2:
the epidemiology worldwide; the disease from an immunology viewpoint and the development of vaccines against the virus.
This 3rd International Alliance for Biological Standardization COVID-19 webinar brought together a broad range of
international stakeholders, including academia, regulators, funders and industry, with a considerable delegation
from low- and middle-income countries, to provide an update on
the virology, epidemiology and immunology of, and the vaccine development for SARS-CoV-2,
six months after the previous webinar.
Although SARS-CoV-2 shows limited evolution, which is beneficial for vaccine development,
recombination of SARS-CoV-2 with another CoV has led to enhanced human-to-human transmissibility of the virus.
Read the Meeting Report
SARS-CoV-2 CHIM Webinar - June 23, 2020
Controlled Human Infection Models (CHIM):
Ethics, Challenge Agent Production, and Regulatory Issues
June 23rd, 2020 : 14:00-18:00 CEST
IABS has been asked to organize several webinars in order to share scientific information on SARS-CoV-2.
The first IABS webinar (Wednesday May 27th,14:00-16:00 CEST) provided an insight to what was known to date about
the epidemiology worldwide, the disease from an immunology viewpoint and progress regarding the development of vaccines against the virus.
The second IABS SARS CoV-2 webinar was devoted to the use of controlled human infection models (CHIM) to accelerate development and market authorization assessment of vaccines against the virus. The webinar consisted of four brief presentations to set the stage, followed by three panel discussions on ethics, challenge agent production
and quality control issues (CMC) and regulatory issues, and provided ample time for discussion between panelists and participants.
The webinar was organized under the Chatham House Rule (https://www.chathamhouse.org): participants are free to use the information received, but neither the identity nor the affiliation of the speaker(s), nor that of any other participant, may be revealed.
The next IABS SARS CoV-2 webinar: Friday, October 16, 2020.
SARS-CoV-2 Webinar - May 27, 2020
Update on SARS-CoV-2
May 27th, 2020 : 14:00 CEST
IABS has been asked to organize several webinars in order to share scientific information on SARS-CoV-2.
As science is evolving day after day, it is important for many people to have an overview of the actual knowledge at a specific moment in time.
The first IABS webinar that took place Wednesday May 27th from 14:00-16:00 CEST gave you an insight to what is known about SARS-CoV-2, the epidemiology worldwide, the disease from an immunology viewpoint and where we are today with the development of vaccines against the virus.
This webinar is the first in a series of webinars to inform our network on what is known about the virus, the disease, and how to cope with it.
The recording of the webinar is available below:
IABS 65th Anniversary Conference on Infectious Diseases - February 26-28, 2020
New paths for sustainable solutions to tackle global and emerging infectious threats
IABS celebrated its 65th Anniversary on February 26-28, 2020, in Lyon, France.
3rd Human Challenge Trials in Vaccine Development - February 6-7, 2020
3rd Human Challenge Trials in Vaccine Development
5th Cell Therapy Conference, Tokyo, Japan - February 4-5, 2020
5th IABS Cell Therapy Conference
Towards international convergence of basic technical requirements
and evaluation of human cell therapy products
Muromachi Mitsui Hall & Conference
Organized by: International Alliance for Biological Standardization (IABS)
With the support from: Osaka University Graduate School of Medicine
Animal Testing for Vaccines, Bangkok, Thailand - December 3-4, 2019
Animal Testing for Vaccines
Implementing Replacement, Reduction and Refinement:
Challenges and Priorities
2nd Setting Specifications for Biological Products - December 2-3, 2019
2nd Setting Specifications for Biological Products: A Pathway to Harmonization
2nd Conference on Next Generation Sequencing for Adventitious Virus Detection in Human and Veterinary Biologics - November 13-14, 2019
2nd Conference on Next Generation Sequencing
for Adventitious Virus Detection in
Human and Veterinary Biologics
An IABS-EU Meeting
Quality Requirements for Challenge Agents - October 22, 2019
Quality Requirements for Challenge Agents
An IABS-EU Meeting
Towards Rabies Elimination in Asia-Pacific – From Theory to Practice, Bangkok, Thailand - September 25-26, 2019
Towards Rabies Elimination in Asia-Pacific – From Theory to Practice
The meeting aims at snowballing efforts and achieving substantial progress in rabies control in the Asia-Pacific region of the world in the near future. As the key focus is placed on canine rabies the meeting will be an important contribution to the initiative of the United Against Rabies collaboration of the World Health Organization (WHO), World Organisation for Animal Health (OIE), Food and Agriculture Organization of the United Nations (FAO), and Global Alliance for Rabies Control (GARC) of ending human dog-mediated rabies by 2030. Recognized international and local experts will give insights into state-of-the art intersectoral One Health approaches, standards, available tools and guidelines developed by international organizations and institutions and best-practice examples from the region on how to prevent human rabies by eliminating rabies at its animal source. As such the meeting provides a platform for health and veterinary services, managers of national and local rabies eliminations programs, researchers and other people interested in advancing knowledge of rabies surveillance, prevention and control, to meet each other, to share their experience and also to discuss challenges to overcome. The meeting is considered to be a starting point for a continuous professional exchange on the way to a rabies free Asia-Pacific.
Scientific Committee :
Dr Charung Muangchana Director, National Veterinary Institute, Thailand
Dr Karoon Chanachai, Department of Livestock Development (DLD), Thailand
Dr Thomas Müller, Chair Friedrich-Loeffler-Institut, Germany
Dr Conrad Freuling, Friedrich-Loeffler-Institut, Germany
Dr Bernadette Abela-Ridder, World Healandh Organization
Dr Ivana Knezevic, World Health Organization
Dr Gregorio Torres, World Organization for Animal Health (OIE)
Dr Katinka de Balogh, Food and Agricultural Organization of the UN (FAO)
Dr Carmen Jungbäck, International Alliance for Biological Standardization (IABS)
Dr Gowri Yale, Mission Rabies
Prof. Louis Nel,Global Alliance for Rabies Control
Dr Ryan Wallace, Centres for Disease Control and Prevention, USA
Diagnostics in the Veterinary Field - May 15-17, 2019
Diagnostics in the Veterinary Field:
The Role in Health Surveillance and Disease Identification
A workshop focusing on advantages / benefits and disadvantages
and gaps of the current methods and methodologies
Implementing Nonanimal Approaches to Human and Veterinary Vaccine Testing - October 16-17, 2018
Workshop: Implementing Non-animal Approaches to Human and Veterinary Vaccine Testing:
Achieving Scientific and Regulatory Success for Rabies and Beyond
October 16-17, 2018
National Institutes of Health, Bethesda, Maryland
5th Statistical Approaches for CMC Development and Lifecycle Management of Biotherapeutics and Vaccines - November 26-28, 2018
5th Statistical Approaches for CMC Development and
Lifecycle Management of Biotherapeutics and Vaccines
November 26-28, 2018
Venue: US Pharmacopeia
This meeting is to bring together regulators and scientists to discuss statistical approaches used to help develop and manage processes, which ensure the quality and availability of biotherapeutics and vaccines. Speakers and panel members will engage with meeting participants on challenges and solutions related to CMC development and lifecycle management of biologics. Areas of attention will include Quality by Design in process and analytical development, comparability and biosimilarity, stability study design and analysis, validation, and continuous process and analytical verification. Statistical challenges related to introduction of new technologies and Big Data will be discussed. Special emphasis will be devoted to collaboration and communication, between scientists and statisticians as well as industry and regulators. The meeting will bring experts together to discuss the issues and through roundtables attempt to reach conclusions that will add value to global public health.
ZAPI Stakeholders Final Conference - Slides request
Please complete the following form to request the slides from the ZAPI Stakeholders Final Conference.
Narcolepsy and Pandemic Influenza Vaccination - March 26-27, 2018
Narcolepsy and Pandemic Influenza Vaccination
What we know and what we need to know before the next Pandemic
March 26-27, 2018
Eurostation II, Place Victor Horta
In partnership with
Federal Agency for Medicines and Health Products (FAMHP)
Vaccine Center of Excellence
This meeting was held under Chatham House Rule
Influenza Pandemics occur when an influenza strain circulates that humans have not been exposed to before. This may lead to widespread circulation and a high case fatality rate.
In 2009 pandemic, several H1N1 vaccines were developed against the new H1N1 virus and were extensively used. In Finland and Sweden an increase in narcolepsy was noted after the mass vaccination with one of these vaccines. Disparate results were seen in other countries with other vaccines. In addition, an increase of narcolepsy has been reported in countries in Asia following wild type influenza infection.
The goal of this meeting is to be prepared for the next pandemic:
- What are the latest data on the risk of narcolepsy following exposure to 2009 pandemic vaccines?
- What scientific data are available and what data are lacking to explain the phenomena that was seen in 2009-10?
- What additional work is needed to prepare for potential use of adjuvanted vaccines for a future pandemic ?